| Death | Local recurrence | Distant metastasis | ||||||
---|---|---|---|---|---|---|---|---|---|
aHR* | (95% CI) | P value | aHR* | (95% CI) | P value | aHR* | (95% CI) | p value | |
Adjuvant RT | |||||||||
 No | Ref |  | 0.0003 | Ref |  | 0.0356 | Ref |  | 0.6854 |
 Yes | 0.52 | (0.37–0.74) |  | 0.90 | (0.79–0.96) |  | 0.89 | (0.54–1.50) |  |
Age | |||||||||
 20–69 | Ref |  | 0.0020 | Ref |  | 0.1200 | Ref |  | 0.2901 |
 70+ | 1.63 | (1.20–2.22) |  | 1.29 | (0.81–2.49) |  | 0.75 | (0.44–1.28) |  |
Diagnosis year | |||||||||
 2009–2012 | Ref |  | 0.3507 | Ref |  | 0.2770 | Ref |  | 0.7421 |
 2013–2016 | 0.79 | (0.69–1.31) |  | 0.73 | (0.58–1.21) |  | 0.81 | (0.57–1.75) |  |
CCI scores | |||||||||
 0 | Ref |  | 0.0322 | Ref |  | 0.1434 | Ref |  | 0.2112 |
 1 | 1.26 | (1.14–1.97) |  | 1.21 | (0.92–1.79) |  | 1.35 | (0.85–1.97) |  |
Differentiation | |||||||||
 I | Ref |  | 0.0177 | Ref |  | 0.0146 | Ref |  | 0.0046 |
 II | 1.09 | (1.01–1.60) |  | 1.36 | (1.02–3.59) |  | 1.36 | (1.02–3.59) |  |
 III | 1.47 | (1.09–2.40) |  | 1.37 | (1.11–3.71) |  | 1.37 | (1.01–3.71) |  |
pT | |||||||||
 pT1 | Ref |  | < 0.0001 | Ref |  | 0.0016 | Ref |  | 0.0196 |
 pT2 | 1.38 | (1.07–1.97) |  | 1.35 | (1.05–3.12) |  | 1.09 | (1.04–3.04) |  |
 pT3–4 | 2.91 | (1.90–4.44) |  | 2.62 | (1.19–4.72) |  | 2.35 | (1.13–4.89) |  |
pN | |||||||||
 pN0 | Ref |  | < 0.0001 | Ref |  | 0.0040 | Ref |  | 0.0082 |
 pN1 | 1.94 | (1.38–2.72) |  | 1.09 | (1.03–1.41) |  | 2.38 | (1.37–4.12) |  |
 pN2–3 | 2.90 | (2.01–4.18) |  | 1.26 | (1.06–1.37) |  | 1.88 | (1.01–3.51) |  |
Hypertension | 1.08 | (0.77–1.81) | 0.4882 | 0.90 | (0.59–1.56) | 0.7217 | 0.95 | (0.69–1.48) | 0.8021 |
CAD | 1.11 | (0.71–1.92) | 0.3427 | 0.84 | (0.53–1.39) | 0.6914 | 0.94 | (0.78–1.59) | 0.3426 |
Diabetes | 1.11 | (0.73–1.90) | 0.3422 | 1.01 | (0.70–1.51) | 0.4521 | 0.90 | (0.55–1.91) | 0.8909 |
Hormone receptor positive | 0.87 | (0.80–0.91) | 0.0312 | 0.77 | (0.45–0.82) | 0.0204 | 0.72 | (0.63–0.97) | 0.0322 |
Trastuzumab use | 1.07 | (0.87–1.42) | 0.34661 | 1.09 | (0.58–2.01) | 0.3831 | 1.06 | (0.81–1.54) | 0.3421 |
Anthracycline-based chemotherapy | 0.94 | (0.57–1.88) | 0.4065 | 0.93 | (0.78–1.83) | 0.2412 | 0.84 | (0.70–2.20) | 0.1683 |
Nodal surgery | |||||||||
 ALND | Ref |  | 0.3322 | Ref |  | 0.2434 | Ref |  | 0.2112 |
 SLNB | 1.06 | (0.54–1.09) |  | 1.01 | (0.82–1.79) |  | 1.15 | (0.85–2.97) |  |
Hospital level | |||||||||
 Academic center | Ref |  | 0.2177 | Ref |  | 0.2177 | Ref |  | 0.8146 |
 Nonacademic center | 0.99 | (0.61–1.60) |  | 0.99 | (0.61–1.60) |  | 1.36 | (0.52–3.59) |  |